CClinicalTrials.gg
CompletedNCT07842783Updated Sep 25, 2026

Norepinephrine Infusion vs Bolus vs Ephedrine for Blood Pressure Stability During Cesarean Delivery in Women With Preeclampsia

An interventional study of Norepinephrine (0.05 μg/kg/min) and Norepinephrine 4mcg in Preeclampsia, Hypotension During Spinal Anesthesia for Cesarean Delivery and Hemodynamic Instability, sponsored by Benha University. Completed at 1 site in Egypt. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Benha University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This randomized controlled trial will compare norepinephrine infusion, norepinephrine bolus, and ephedrine bolus for maintaining hemodynamic stability during spinal anesthesia for scheduled cesarean delivery in women with preeclampsia. Eighty-four eligible women will be randomly allocated in a 1:1:1 ratio to one of three treatment groups. The primary outcome is hemodynamic control during the first 20 minutes after spinal anesthesia, including the occurrence of hypotension, need for rescue vasopressors, and maintenance of blood pressure within ±20% of baseline. Secondary outcomes include severe hypotension, time to first hypotensive episode, vasopressor requirements, maternal adverse effects, fluid balance, and neonatal outcomes including Apgar scores, umbilical cord blood gases, and NICU admission.

Read the detailed description

Preeclampsia is associated with hemodynamic changes that may complicate blood pressure management during cesarean delivery under spinal anesthesia. Norepinephrine may be administered either as an infusion or intermittent boluses, while ephedrine is another commonly used vasopressor strategy. This study is designed to directly compare these approaches in women with preeclampsia undergoing scheduled cesarean delivery under spinal anesthesia.

This is a prospective, randomized controlled trial that will be conducted at Benha University Hospital. A total of 84 women with preeclampsia will be enrolled and randomly allocated in a 1:1:1 ratio to three groups. The norepinephrine infusion group will receive a prophylactic norepinephrine infusion starting at 0.05 µg/kg/min with titration to maintain systolic blood pressure at or above 80% of baseline. The norepinephrine bolus group will receive 4 µg intravenous norepinephrine boluses when systolic blood pressure falls below 80% of baseline. The ephedrine group will receive 6 mg intravenous ephedrine boluses under the same hypotension criterion. Rescue measures are specified in the study protocol for refractory hypotension.

All participants will undergo pre-anesthetic assessment and intraoperative monitoring including electrocardiography, non-invasive blood pressure monitoring, and pulse oximetry. Spinal anesthesia will be performed using hyperbaric bupivacaine with fentanyl. Hemodynamic monitoring will continue during the procedure and for 2 hours postoperatively.

The primary outcome is hemodynamic control during the first 20 minutes after spinal anesthesia, assessed by hypotension episodes, the need for additional rescue vasopressors, and maintenance of blood pressure within ±20% of baseline. Secondary outcomes include severe hypotension, hypertensive episodes, time to first hypotensive episode, total vasopressor requirements, bradycardia, tachycardia, nausea or vomiting, fluid balance, umbilical cord blood gas measurements, Apgar scores at 1 and 5 minutes, and NICU admission.

02

Conditions studied

  • Preeclampsia
  • Hypotension During Spinal Anesthesia for Cesarean Delivery
  • Hemodynamic Instability

Browse trials for

Keywords

  • Preeclampsia
  • Cesarean section
  • Spinal anesthesia
  • Norepinephrine
  • Norepinephrine infusion
  • Norepinephrine bolus
  • Ephedrine
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

Women older than 18 years of age with preeclampsia. American Society of Anesthesiologists (ASA) physical status II-III. Preeclampsia defined by systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg on two measurements at least 4 hours apart in a previously normotensive woman, accompanied by proteinuria (≥300 mg/24 hours or equivalent) or evidence of end-organ dysfunction, such as thrombocytopenia, renal or hepatic impairment, pulmonary edema, or neurological symptoms.

Singleton pregnancy. Gestational age ≥37 weeks. Scheduled cesarean delivery under spinal anesthesia.

Exclusion criteria

Exclusion Criteria:

Refusal to participate in the study. Chronic hypertension or chronic hypertension with preeclampsia. Comorbid conditions, including diabetes mellitus or cardiovascular disease. Suspected fetal compromise. Emergency cesarean section.

04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Norepinephrine Infusion

    Participants will receive a prophylactic intravenous norepinephrine infusion at 0.05 µg/kg/min, started immediately after spinal injection and titrated by ±0.02 µg/kg/min every 2 minutes to maintain systolic blood pressure at or above 80% of baseline. If hypotension persists despite two vasopressor doses or infusion adjustments, the infusion rate may be increased by 0.02-0.05 µg/kg/min according to the study rescue protocol.

    Drug: Norepinephrine (0.05 μg/kg/min)

  • Active comparator
    Norepinephrine Bolus

    Participants will receive intravenous norepinephrine 4 µg as a bolus when systolic blood pressure falls below 80% of baseline, repeated every 2 minutes as needed. If hypotension persists after two vasopressor doses, the norepinephrine bolus may be escalated to 6 µg according to the study rescue protocol.

    Drug: Norepinephrine 4mcg

  • Active comparator
    Ephedrine Bolus

    Participants will receive intravenous ephedrine 6 mg as a bolus when systolic blood pressure falls below 80% of baseline, repeated every 3 minutes as needed. If hypotension persists after two vasopressor doses, the ephedrine bolus may be escalated to 10 mg according to the study rescue protocol.

    Drug: Ephedrine Bolus 6 mg

Interventions

  • DrugNorepinephrine (0.05 μg/kg/min)

    Participants will receive a prophylactic intravenous norepinephrine infusion at 0.05 µg/kg/min, started immediately after spinal injection and titrated by ±0.02 µg/kg/min every 2 minutes to maintain systolic blood pressure at or above 80% of baseline. If hypotension persists despite two vasopressor doses or infusion adjustments, the infusion rate may be increased by 0.02-0.05 µg/kg/min according to the study rescue protocol.

  • DrugNorepinephrine 4mcg

    Participants will receive intravenous norepinephrine 4 µg as a bolus when systolic blood pressure falls below 80% of baseline, repeated every 2 minutes as needed. If hypotension persists after two vasopressor doses, the norepinephrine bolus may be escalated to 6 µg according to the study rescue protocol.

  • DrugEphedrine Bolus 6 mg

    Participants will receive intravenous ephedrine 6 mg as a bolus when systolic blood pressure falls below 80% of baseline, repeated every 3 minutes as needed. If hypotension persists after two vasopressor doses, the ephedrine bolus may be escalated to 10 mg according to the study rescue protocol.

05

What researchers measure

Primary outcomes

  1. Incidence of Hypotension During the First 20 Minutes After Spinal Anesthesia

    The number and proportion of participants experiencing at least one episode of hypotension during the first 20 minutes after spinal anesthesia. Hypotension is defined in the study protocol as systolic blood pressure below 80% of the participant's baseline value.

    Time frame: From spinal anesthesia administration through 20 minutes after spinal anesthesia

Secondary outcomes

  1. the incidence of severe hypotension

    severe hypotension defined as (SBP\<70% baseline)

    Time frame: From spinal anesthesia administration and through the surgery

  2. Need for Additional Rescue Vasopressors

    The proportion of participants who require additional rescue vasopressor administration during the first 20 minutes after spinal anesthesia because of inadequate blood pressure control.

    Time frame: During the First 20 Minutes After Spinal Anesthesia

  3. time to first hypotensive episode

    (minutes from spinal injection)

    Time frame: after spinal anesthesia and throughout the surgery

06

Study locations

1 site
  • Benha University Hospital
    Banhā, Egypt
07

References and documents

Individual participant data

Plan to share: Undecided — A decision regarding sharing of individual participant data with other researchers has not yet been made.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07842783
Lead sponsor
Benha University
Responsible party
Samar Rafik Mohamed Amin (Assistant Professor of Anesthesia, Faculty of Medicine, Benha University, Benha University) — Principal investigator
First posted
Sep 25, 2026
Start date
Jul 18, 2025
Primary completion
Jun 18, 2026
Completion
Jul 18, 2026
Last update
Sep 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion